Phase 3 Parkinson's Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with advanced or returning endometrial cancer (cancer of the lining of the uterus) that has been confirmed through a tissue sample, and whose cancer has a specific biological feature called "proficient mismatch repair" (pMMR) — meaning the cancer's repair system is working normally.
• People whose cancer can be seen and measured (or in some cases just detected) on scans, meeting specific staging criteria as assessed by the trial investigator.
• People who have not previously received systemic (whole-body) treatment for endometrial cancer, with limited exceptions: one prior course of platinum-based chemotherapy given with the intent to cure, prior radiation therapy (with or without chemotherapy used to boost radiation effects) completed more than 2 weeks before the trial starts, or prior hormonal therapy that was stopped at least 1 week before the trial starts.

Who may not be able to join:

• People whose uterine cancer is a specific type called carcinosarcoma, neuroendocrine tumour, endometrial sarcoma, stromal sarcoma, leiomyosarcoma, adenosarcoma, or other sarcoma types.
• People whose endometrial cancer has a biological feature called "mismatch repair deficient" (dMMR) — meaning the cancer's repair system is not working properly.
• People for whom doctors consider surgery to completely remove all tumours, or curative-intent radiation therapy, to be a suitable option at the time of enrolment.
• People who have a history of serious dry eye syndrome, severe disease of the glands along the eyelid edges, severe inflammation of the eyelids, or severe corneal (eye surface) conditions that affect healing.
• People who have active inflammatory bowel disease currently requiring medications that suppress the immune system, or who have a history of inflammatory bowel disease.
• People with serious, uncontrolled heart or blood vessel disease, or uncontrolled disease affecting blood vessels in the brain.
• People who are living with HIV and also have a history of a condition called Kaposi's sarcoma or Multicentric Castleman's Disease.
• People who have previously received certain types of treatments, including: immune checkpoint therapies targeting specific proteins on immune cells (such as anti-PD-1 or anti-PD-L1 agents); certain antibody-drug treatments targeting a protein called TROP-2; or antibody-drug treatments containing a substance called a topoisomerase I inhibitor.

Important: Always verify eligibility with the trial site directly before applying.